Drug clinical trial reporting still dangerously inadequate, says BMJ
This article was originally published in SRA
The British Medical Journal has published seven research papers that provide a damning indictment of current practice in pharmaceutical clinical trial reporting1. According to an accompanying editorial by senior research fellow Richard Lehman and clinical epidemiology editor Elizabeth Loder, the articles confirm that "a large proportion of evidence from human trials is unreported, and much of what is reported is done so inadequately"2. They contend that this leads to unnecessary harm to patients and costs to health systems.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.